Compare New York Times Co (NYT) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
New York Times Co vs Smith & Nephew plc — how do they compare? New York Times Co trades at $63.74 (market cap $10.28B), while Smith & Nephew plc trades at $29.83 (market cap $12.54B). The key difference: Smith & Nephew plc is the larger of the two by market cap, and Smith & Nephew plc pays the higher dividend (2.65%). Which is the better fit depends on your goals.
| NYT | SNN | |
|---|---|---|
Market Cap | $10.28B | $12.54B |
Sector | Media | Health |
52-Week High | $85.86 | $38.70 |
52-Week Low | $54.66 | $28.73 |
Enterprise Value | $9.67B | $15.57B |
Dividend Yield | 1.44% | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The New York Times (NYT) stock trades at $64.21, down 0.91% on the day, with a bearish technical signal despite recent earnings beats. Revenue growth remains steady, reaching $2.82 billion in 2025, with net income margins improving to 12.17%. The company faces headwinds from slowing digital subscriber growth, as highlighted in recent quarterly reports, but maintains strong profitability and cash flow generation.
Outlook is mixed; valuation appears full with a P/E of 26.55, yet analyst consensus targets $77.50 suggest upside. Key risks include subscriber growth moderation and competitive pressures. The stock offers a dividend yield with the next payment scheduled for July 23, 2026.
Smith & Nephew (SNN) trades at $29.76, down 1.06% with bearish technical signals. The company shows improving fundamentals with revenue growth from $5.8B to $6.2B and net income margin expanding to 10.08% in 2025. Recent Q2 2026 earnings beat expectations but the company lowered full-year revenue guidance from 6% to 4% growth due to U.S. Orthopaedics weakness.
While valuation multiples appear reasonable (P/E 20.41, EV/EBITDA 9.9), the stock faces headwinds from mixed earnings performance and cautious analyst sentiment. The primary investment case hinges on execution in robotics and wound care segments offsetting orthopedic challenges, with downside risk from continued U.S. market softness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
